News
-
-
PRESS RELEASE
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Sonnet BioTherapeutics Holdings, Inc. initiates review of strategic alternatives to maximize stockholder value with financial advisor Chardan Capital Markets. Evaluation may lead to various strategic transactions but no definitive decisions made yet -
-
PRESS RELEASE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics reports positive safety and efficacy data from Phase 1 clinical trials of SON-1010, a novel immunotherapeutic drug for solid tumors, demonstrating extended half-life and clinical benefit in patients -
-
PRESS RELEASE
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Sonnet BioTherapeutics announces financial results and corporate updates including Phase 1 data on SON-1010 safety, net proceeds from tax program, and clinical trial progress on SON-080 for CIPN -
-
-
-
PRESS RELEASE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Sonnet BioTherapeutics to present preclinical data on SON-080 for neuropathies at AACR Annual Meeting 2024. The study focuses on safety and clinical plans using recombinant human Interleukin-6
